156 related articles for article (PubMed ID: 21311691)
1. Vitamin D and responses to inhaled fluticasone in severe chronic obstructive pulmonary disease.
Kunisaki KM; Rector TS
Int J Chron Obstruct Pulmon Dis; 2011 Jan; 6():29-34. PubMed ID: 21311691
[TBL] [Abstract][Full Text] [Related]
2. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study.
Kunisaki KM; Rice KL; Janoff EN; Rector TS; Niewoehner DE
Ther Adv Respir Dis; 2008 Apr; 2(2):55-64. PubMed ID: 19124359
[TBL] [Abstract][Full Text] [Related]
3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
[TBL] [Abstract][Full Text] [Related]
5. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Lung; 2006; 184(4):217-22. PubMed ID: 17006748
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
8. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
9. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids.
Wolfe J; Rooklin A; Grady J; Munk ZM; Stevens A; Prillaman B; Duke S; Harding S
J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1153-61. PubMed ID: 10856150
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, determinants and clinical correlates of vitamin D deficiency in patients with Chronic Obstructive Pulmonary Disease in London, UK.
Jolliffe DA; James WY; Hooper RL; Barnes NC; Greiller CL; Islam K; Bhowmik A; Timms PM; Rajakulasingam RK; Choudhury AB; Simcock DE; Hyppönen E; Walton RT; Corrigan CJ; Griffiths CJ; Martineau AR
J Steroid Biochem Mol Biol; 2018 Jan; 175():138-145. PubMed ID: 28161533
[TBL] [Abstract][Full Text] [Related]
11. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
[TBL] [Abstract][Full Text] [Related]
12. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance-associated protein 1 and lung function decline with or without long-term corticosteroids treatment in COPD.
Budulac SE; Postma DS; Hiemstra PS; Lapperre TS; Kunz LI; Vonk JM; Marike Boezen H; Timens W;
Eur J Pharmacol; 2012 Dec; 696(1-3):136-42. PubMed ID: 22982023
[TBL] [Abstract][Full Text] [Related]
15. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.
Postma DS; Roche N; Colice G; Israel E; Martin RJ; van Aalderen WM; Grigg J; Burden A; Hillyer EV; von Ziegenweidt J; Gopalan G; Price D
Int J Chron Obstruct Pulmon Dis; 2014; 9():1163-86. PubMed ID: 25378918
[TBL] [Abstract][Full Text] [Related]
16. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.
Miller DP; Watkins SE; Sampson T; Davis KJ
Phys Sportsmed; 2010 Dec; 38(4):19-27. PubMed ID: 21150138
[TBL] [Abstract][Full Text] [Related]
17. Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.
Rodriguez-Roisin R; Tetzlaff K; Watz H; Wouters EF; Disse B; Finnigan H; Magnussen H; Calverley PM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1973-81. PubMed ID: 27578972
[TBL] [Abstract][Full Text] [Related]
18. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
[TBL] [Abstract][Full Text] [Related]
19. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
[TBL] [Abstract][Full Text] [Related]
20. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
